Peginterferon alfa-2a
- Generic Name
- Peginterferon alfa-2a
- Brand Names
- Pegasys
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 198153-51-4
- Unique Ingredient Identifier
- Q46947FE7K
- Background
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting...
- Indication
Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease . May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
...
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, HBeAg Positive Chronic Hepatitis B
- Associated Therapies
- -
Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2014-09-04
- Target Recruit Count
- 770
- Registration Number
- NCT01884402
- Locations
- 🇪🇸
Fundación Pública Andaluza para la Gestión de la investigación en salud de Sevilla (FISEVI), Sevilla, Spain
A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1669
- Registration Number
- NCT01855997
- Locations
- 🇦🇹
Medizinische Universität Wien; Univ.Klinik für Innere Medizin III - Gastroenterologie & Hepatologie, Wien, Austria
🇨🇳The First Affiliate Hospital of Guangxi Medical University, Nanning, China
🇨🇳Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials
- Conditions
- Interventions
- First Posted Date
- 2013-05-14
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 272
- Registration Number
- NCT01853254
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure
- Conditions
- Interventions
- First Posted Date
- 2013-02-26
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 282
- Registration Number
- NCT01798576
Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis
- First Posted Date
- 2013-01-01
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 8
- Registration Number
- NCT01758588
- Locations
- 🇺🇸
Weill Medial College of Cornell Universiy, New York, New York, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 54
- Registration Number
- NCT01753557
- Locations
- 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan
HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin
- Conditions
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Anna Cruceta
- Target Recruit Count
- 128
- Registration Number
- NCT01718301
- Locations
- 🇪🇸
Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- King Abdulaziz Medical City
- Target Recruit Count
- 181
- Registration Number
- NCT01686789
- Locations
- 🇸🇦
King Khaled University Hospital, Riyadh, Saudi Arabia
🇸🇦King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
🇸🇦King Abdulaziz Medical City, Riyadh, Saudi Arabia
A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 516
- Registration Number
- NCT01659567
- Locations
- 🇬🇪
Hepatology Clinic Hepa, Tbilisi, Georgia
🇬🇪Ltd Mrcheveli, Tbilisi, Georgia
🇬🇪Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia
Dose Ranging of GSK2336805 in Combination Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 286
- Registration Number
- NCT01648140
- Locations
- 🇵🇷
GSK Investigational Site, San Juan, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.